Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients. The Australian cancer-treatment company said Monday the median rate for overall ...

Global and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is ...

We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look ...

The All Ordinaries Index (ASX: XAO) is down 0.3% today despite the best efforts of this rocketing ASX All Ords share. Here’s ...

FDA meeting requested following Phase IIb trial showing median overall survival of 17.6 months without chemotherapy Immutep ...

While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...

U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

"Heidi's leadership in driving growth, enhanced by digital innovation, along with her strategic and operational expertise ...

In 2010, the Obama administration opened the floodgates to government waste by changing the rules to allow 340B hospitals to include contract pharmacies and other provider types. Nonprofit hospitals ...